Primecap Management Co. CA Cuts Stock Position in Eli Lilly and Company $LLY

Primecap Management Co. CA cut its holdings in Eli Lilly and Company (NYSE:LLY) by 11.2% in the third quarter, Holdings Channel.com reports. The fund owned 10,795,338 shares of the company’s stock after selling 1,359,570 shares during the quarter. Eli Lilly and Company makes up about 6.3% of Primecap Management Co. CA’s investment portfolio, making the stock its largest position. Primecap Management Co. CA’s holdings in Eli Lilly and Company were worth $8,236,843,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of LLY. Intech Investment Management LLC raised its holdings in shares of Eli Lilly and Company by 18.2% during the 3rd quarter. Intech Investment Management LLC now owns 199,324 shares of the company’s stock valued at $152,084,000 after purchasing an additional 30,632 shares in the last quarter. Catalyst Financial Partners LLC boosted its holdings in Eli Lilly and Company by 0.8% in the third quarter. Catalyst Financial Partners LLC now owns 5,166 shares of the company’s stock worth $3,942,000 after purchasing an additional 42 shares in the last quarter. Hurley Capital LLC increased its position in Eli Lilly and Company by 12.3% during the third quarter. Hurley Capital LLC now owns 128 shares of the company’s stock worth $98,000 after buying an additional 14 shares during the last quarter. Empirical Asset Management LLC increased its position in Eli Lilly and Company by 129.5% during the third quarter. Empirical Asset Management LLC now owns 3,472 shares of the company’s stock worth $2,649,000 after buying an additional 1,959 shares during the last quarter. Finally, RWA Wealth Partners LLC raised its holdings in Eli Lilly and Company by 1.5% during the third quarter. RWA Wealth Partners LLC now owns 65,481 shares of the company’s stock valued at $49,962,000 after buying an additional 948 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s oral obesity candidate completed an early trial stage, sharpening investor focus on a potential oral GLP‑1/GIP pathway competitor to injectables — a major long‑term revenue lever if translated to late‑stage success. TipRanks: Oral obesity trial completion
• Positive Sentiment: Positive Phase 3 VIVID‑2 open‑label extension results for Omvoh (mirikizumab) bolster Lilly’s non‑GLP‑1 pipeline (Crohn’s/UC), reducing single‑product concentration risk and adding near‑term commercial optionality. Yahoo Finance: VIVID‑2 results
• Positive Sentiment: Analysts have largely stayed constructive: Truist reaffirmed a buy rating and Goldman/Goldman‑coverage notes (and price targets) remain supportive, which can limit downside from headline volatility. MarketScreener: Truist reaffirms buy
• Neutral Sentiment: Bank of America and other firms argue Novo’s announced list‑price cuts are unlikely to meaningfully dent U.S. GLP‑1 volumes for rivals in the near term, suggesting the sector pricing move may be more tactical than market‑eroding. That view helps explain why some investors see the price cut as contained risk rather than an existential threat to Lilly’s sales. Yahoo Finance: BofA sees limited impact
• Neutral Sentiment: Macro/sector coverage pieces and long‑term growth analyses highlight that Lilly’s GLP‑1 blockbusters (Mounjaro/Zepbound) drove a majority of recent revenue growth, keeping the long‑term story intact even as short‑term headlines create choppiness. Zacks: GLP‑1 revenue drivers
• Negative Sentiment: Novo Nordisk announced plans to cut U.S. list prices for Wegovy/Ozempic by up to ~50% starting in 2027 — a direct sector shock that triggered investor worry about pricing pressure, broader margin implications and potential share‑loss dynamics across GLP‑1 makers. That news is the primary reason for today’s downward pressure. Yahoo Finance: Novo halves US price
• Negative Sentiment: Several outlets flagged that investors reacted nervously — and some short‑term selloffs followed — after the Novo pricing announcement and prior trial headlines; that volatility can amplify intraday declines despite Lilly’s strong fundamentals. Fool: Why LLY slumped

Eli Lilly and Company Trading Down 1.1%

Shares of Eli Lilly and Company stock opened at $1,030.30 on Thursday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company’s fifty day simple moving average is $1,054.25 and its 200-day simple moving average is $924.46. The company has a market cap of $971.95 billion, a price-to-earnings ratio of 44.89, a PEG ratio of 1.21 and a beta of 0.39. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business’s revenue was up 42.6% on a year-over-year basis. During the same period in the prior year, the firm earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is 30.15%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Argus upped their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. CICC Research boosted their target price on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a report on Wednesday, February 11th. Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Monday. UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 2nd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,229.33.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.